"We see a continued large engagement in the inclusion of patients in the dose expansion part for the combination fostrox + Lenvima ®, as an attractive treatment option in second-line treatment.

Eisai's thyroid cancer drug Lenvima stepped into the FDA's fast lane for a new use. The agency granted Lenvima priority review as a treatment for advanced kidney cancer, which could be a much more ...

The US Food and Drug Administration (FDA) has approved a combination of MSD’s anti-PD-1 therapy Keytruda (pembrolizumab) plus Eisai’s Lenvima (lenvatinib) for the first-line treatment of adult ...

in hepatocellular carcinoma (HCC), in combination with Lenvima®, was successfully completed. The preliminary results from the dose cohorts are positive with a good safety and tolerability ...

Eisai has gotten its second dose of good news in as many months. Weeks after getting an FDA approval for its thyroid cancer drug Lenvima, the struggling Japanese drugmaker has gotten the nod for ...

"The price at which the recommended starting dose of Lenvima for unresectable HCC will be sold to wholesalers, excluding discounts, is $16,970 for a 30-day supply," Eisai told Reuters. The price ...